Suchen
Roivant Sciences Ltd
ROIVZur Watchlist hinzufügen
38.770USD
-0.220-0.56%
Trading geöffnet 09/22, 11:21（ET）
28.02BMarktkapitalisierung
VerlustKGV TTM
Über {index_name} Roivant Sciences Ltd Unternehmen
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Roivant Sciences Ltd Profil
BörsenkürzelROIV
Name des UnternehmensRoivant Sciences Ltd
IPO-datumDec 03, 2020
CEOVenker (Eric)
Anzahl der mitarbeiter750
WertpapierartOrdinary Share
GeschäftsjahresendeDec 03
Addresse7Th Floor, 50 Broadway
StadtLONDON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited Kingdom
PostleitzahlSW1H 0DB
Telefon4412955950
Websitehttp://roivant.com/
BörsenkürzelROIV
IPO-datumDec 03, 2020
CEOVenker (Eric)
Führungskräfte von Roivant Sciences Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.73M
-11.43%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.37M
-1.01%
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
258.79K
-5146.11%
Dr. Mayukh Sukhatme, M.D.
Dr. Mayukh Sukhatme, M.D.
President, Chief Investment Officer, Director
President, Chief Investment Officer, Director
253.33K
--
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
143.83K
+42.81%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
109.78K
-3.26%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
109.16K
+2.45%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
92.38K
-3.14%
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
84.48K
-6.81%
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
430.00
-479.77%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.73M
-11.43%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.37M
-1.01%
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
258.79K
-5146.11%
Dr. Mayukh Sukhatme, M.D.
Dr. Mayukh Sukhatme, M.D.
President, Chief Investment Officer, Director
President, Chief Investment Officer, Director
253.33K
--
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
143.83K
+42.81%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
109.78K
-3.26%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Roivant Sciences Ltd?
Die fünf größten Anteilseigner von Roivant Sciences Ltd sind: Dr. Keith S. Manchester, M.D.
Wie viele Institutionen halten Anteile an Roivant Sciences Ltd (ROIV)?
Mit Stand vom 2026Q1 halten 781 Institutionen Anteile an Roivant Sciences Ltd, mit einem Gesamtmarktwert von etwa 565.52M, was 79.01% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -23023750.00 gestiegen.